	US 12,016,312 B2
	Animal models, screening methods, and treatment methods for intraocular diseases or disorders
Yan Zhang, Beijing (CN); Lai Wei, Guangdong (CN); and Hui Ouyang, Guangdong (CN)
Assigned to SMILEBIOTEK ZHUHAI LIMITED, Zhuhai (CN)
Appl. No. 17/293,991
Filed by ZHUHAI QIWEI BIO-TECHNOLOGY LTD., Guangdong (CN)
PCT Filed Nov. 12, 2019, PCT No. PCT/CN2019/117444 § 371(c)(1), (2) Date May 14, 2021, PCT Pub. No. WO2020/098630, PCT Pub. Date May 22, 2020.
Claims priority of application No. 201811351660.9 (CN), filed on Nov. 14, 2018; and application No. PCT/CN2018/118929 (WO), filed on Dec. 3, 2018.
Prior Publication US 2022/0015338 A1, Jan. 20, 2022
Int. Cl. A61K 31/085 (2006.01); A01K 67/00 (2006.01); A61K 31/12 (2006.01); A61K 31/235 (2006.01); A61K 31/437 (2006.01); A61K 31/704 (2006.01); C12N 1/20 (2006.01); C12R 1/11 (2006.01); C12R 1/40 (2006.01); G01N 33/50 (2006.01)

CPC A01K 67/00 (2013.01) [A61K 31/085 (2013.01); A61K 31/12 (2013.01); A61K 31/235 (2013.01); A61K 31/437 (2013.01); A61K 31/704 (2013.01); C12N 1/20 (2013.01); G01N 33/5044 (2013.01); A01K 2207/10 (2013.01); A01K 2227/106 (2013.01); A01K 2267/03 (2013.01); C12R 2001/11 (2021.05); C12R 2001/40 (2021.05)]

20 Claims

1. A method comprising:

(i) identifying, or having identified, a subject as being infected with a microorganism in the intraocular space, wherein the subject has age-related macular degeneration (AMD); and

(ii) administering to the subject a therapeutically effective amount of an active compound selected from one of compounds (1)-(8) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the active compound or pharmaceutically acceptable salt thereof, wherein compounds (1)-(8) have the following chemical structures:

wherein the therapeutically effective amount is an amount effective in killing or inhibiting the growth of the microorganism in the intraocular space.